Keyphrases
Breast Cancer
100%
Neoadjuvant Chemotherapy
100%
Aldehyde Dehydrogenase 2 (ALDH2)
100%
Clinical Outcomes
33%
Cyclophosphamide
25%
Tumor
16%
Overall Survival
16%
Disease-free Survival
16%
Recurrence Risk
16%
Residual Cancer Burden
16%
Tissue Microarray
8%
Breast
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
8%
Chemotherapy
8%
Large Cohort
8%
Kaplan-Meier Method
8%
Large Tumors
8%
Tumor Size
8%
Node-positive
8%
Fisher's Exact Test
8%
Statistical Analysis
8%
Tumor Recurrence
8%
Advanced Stage
8%
Neoadjuvant Therapy
8%
Neoadjuvant
8%
Chemotherapy Regimen
8%
Trastuzumab
8%
Breast Cancer Treatment
8%
Primary Breast Cancer
8%
Neoadjuvant Setting
8%
Hormone Receptor-positive
8%
Triple Negative
8%
HER2+
8%
Chemotherapy Adjuvant
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Breast Cancer
100%
Aldehyde Dehydrogenase
100%
Neoplasm
50%
Cyclophosphamide
50%
Malignant Neoplasm
33%
Overall Survival
33%
Disease Free Survival
33%
Recurrent Disease
33%
Disease
16%
Receptor
16%
Chemotherapy Regimens
16%
Tumor Recurrence
16%
Trastuzumab
16%
Cancer Chemotherapy
16%
Medicine and Dentistry
Breast Cancer
100%
Neoadjuvant Chemotherapy
100%
Aldehyde Dehydrogenase
100%
ALDH1A1
100%
Neoplasm
27%
Cyclophosphamide
27%
Malignant Neoplasm
18%
Overall Survival
18%
Recurrent Disease
18%
Disease Free Survival
18%
Tissue Microarray
9%
Receptor
9%
Disease
9%
Kaplan Meier Method
9%
Fisher Exact Test
9%
Tumor Recurrence
9%
Neoadjuvant Therapy
9%
Adjuvant Chemotherapy
9%
Chemotherapy Regimens
9%
Trastuzumab
9%
Breast Cancer Chemotherapy
9%
Immunology and Microbiology
Cyclophosphamide
100%
Overall Survival
66%
Disease Free Survival
66%
Trastuzumab
33%
Tumor Volume
33%